Fungal prophylaxis following reduced-intensity stem cell transplantation (RIST)

Japanese Journal of Medical Mycology

Volumn 45, Issue 4, 2004, Pages 189-202

  Kami, Masahiro ^a   Imataki, Osamu ^a   Taniguchi, Shuichi ^b   Kanemaru, Mineo ^c   Hayashi, Tatsuyuki ^d  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c Higashijyujyo Hosp Dept Hematol   (Japan)

^d TOKYO METROPOLITAN POLICE HOSPITAL   (Japan)

Author keywords

Antifungals; Fungal infection; Prophylaxis; Reduced intensity stem cell transplantation

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; MICONAZOLE; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASPERGILLOSIS; ASPERGILLUS; CANDIDA ALBICANS; CANDIDIASIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; FUSARIUM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; MYCOSIS; NONHUMAN; REVIEW; TRICHOSPORON;

ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; FUSARIUM;

EID: 10044237518     PISSN: 09164804     EISSN: None     Source Type: Journal    
DOI: 10.3314/jjmm.45.189     Document Type: Review

References (191)

1. Armitage JO: Bone marrow transplantation, N Engl J Med 330(12): 827-838, 1994.
2. Bearman SI, Appelbaum FR, Buckner CD, et al.: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6(10): 1562-1568, 1988.
3. Ferrara JL, Deeg HJ: Graft-versus-host disease. N Engl J Med 324(10): 667-674, 1991.
4. Horowitz MM, Gale RP, Sondel PM, et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3): 555-562, 1990.
5. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ: Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103: 767-776, 2004.
6. Mehta J, Singhal S: Graft-versus-myeloma, Bone Marrow Transplant 22(9): 835-843, 1998.
7. Slavin S, Nagler A, Naparstek E, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3): 756-763, 1998.
8. Giralt S, Estey E, Albitar M, et al.: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89(12): 4531-4536, 1997.
9. Niederwieser D, Maris M, Shizuru JA, et al.: Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101(4): 1620-1629, 2003.
10. Saito T, Kanda Y, Kami M, et al.: Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res 8(4): 1014-1020, 2002.
11. Carella AM, Cavaliere M, Lerma E, et al.: Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 18(23): 3918-3924, 2000.
12. Tanimoto TE, Kusumi E, Hamaki T, et al.: High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. Bone Marrow Transplant 32(2): 131-137, 2003.
13. Childs R, Chernoff A, Contentin N, et al.: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343(11): 750-758, 2000.
14. Bregni M, Dodero A, Peccatori J, et al.: Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99(11): 4234-4236, 2002.
15. Biaise DP, Bay JO, Faucher C, et al.: Reduced intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2003.
16. Maris MB, Niederwieser D, Sandmaier BM, et al.: HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102(6): 2021-2030, 2003.
17. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE: Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102(5): 1915-1919, 2003.
18. Wagner JE, Barker JN, DeFor TE, et al.: Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100 (5): 1611-1618, 2002.
19. Wingard JR: Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 5(2): 55-68, 1999.
20. Wingard JR: Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 20(1): 115-125, 1995.
21. Kami M, Kishi Y, Hamaki T, et al.: The value of the chest computed tomography halo sign in the diagnosis of invasive pulmonary aspergillosis. An autopsy-based retrospective study of 48 patients. Mycoses 45(8): 287-294, 2002.
22. Marr KA, Carter RA, Crippa F, Wald A, Corey L: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34(7): 909-917, 2002.
23. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K: Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33(1): 23-32, 1996.
24. Denning DW; Invasive aspergillosis. Clin Infect Dis 26 (4): 781-803; quiz 804-805, 1998.
25. Marr KA, Carter RA, Boeckh M, Martin P, Corey L: Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100(13): 4358-4366, 2002.
26. Kami M, Fukui T, Ogawa S, et al.: Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 33(9): 1504-1512, 2001.
27. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M: Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97(6): 1604-1610, 2001.
28. Stynen D, Goris A, Sarfati J, Latge JP: A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 33(2): 497-500, 1995.
29. Kami M, Tanaka Y, Kanda Y, et al.: Computed tomographic scan of the chest, latex agglutination test and plasma (1-3)- β-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Haematologica 85(7): 745-752, 2000.
30. Denning DW: Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 23(3): 608-615, 1996.
31. Wald A, Leisenring W, van Burik JA, Bowden RA: Epidemiology of Aspergittus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175(6): 1459-1466, 1997.
32. Ribaud P, Chastang C, Latge JP, et al.: Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 28 (2): 322-330, 1999.
33. Denning DW, Marinus A, Cohen J, et al.: An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 37(2): 173-180, 1998.
34. Ochs L, Shu XO, Miller J, et al.: Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood 86(10): 3979-3986, 1995.
35. Fukuda T, Boeckh M, Carter RA, et al.: Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 102(3): 827-833, 2003.
36. Kojima R, Kami M, Nannya Y, et al.: Evaluation of Late Occurring Invasive Pulmonary Aspergillosis (IPA) after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) by High-Resolution Computed Tomography (HR-CT) (Abstract 3629). Blood 102(11), 2003.
37. Cohen MS, Isturiz RE, Malech HL, et al.: Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med 71(1): 59-66, 1981.
38. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA: Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 100 (3): 345-351, 1984.
39. Morrison BE, Park SJ, Mooney JM, Mehrad B: Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. J Clin Invest 112(12): 1862-1870, 2003.
40. Uzun O, Anaissie EJ: Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood 86(6): 2063-2072, 1995.
41. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 6(6a): 659-713; 715; 717-727; quiz 729-733, 2000.
42. Imataki O, Kami M, Gotoh M, et al.: A Nationwide Survey on Deep Fungal Infections and Antifungal Prophylaxis for Patients Undergoing Hematopoietic Stem-Cell Transplantation (HSCT): Revisit of the Guidelines from the Centers for Disease Control and Prevention (CDC). (Abstract 5507). Blood 102(11), 2003.
43. Mahfouz T, Anaissie E: Invasive fungal infections: New development in prevention, diagnosis and management. In: Hematology 2003. Washington, DC.: Washington DC: American Society for Microbiology; p.445-458, 2003.
44. Pfaller MA: Epidemiology of fungal infections: the promise of molecular typing. Clin Infect Dis 20(6): 1535-1539, 1995.
45. Oren I, Haddad N, Finkelstein R, Rowe JM: Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 66(4): 257-262, 2001.
46. Loo VG, Bertrand C, Dixon C, et al.: Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit. Infect Control Hosp Epidemiol 17(6): 360-364, 1996.
47. Sherertz RJ, Belani A, Kramer BS, et al.: Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med 83(4): 709-718, 1987.
48. Passweg JR, Rowlings PA, Atkinson KA, et al.: Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 21(12): 1231-1238, 1998.
49. Anaissie EJ, Stratton SL, Dignani MC, et al.: Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 34(6): 780-789, 2002.
50. Anaissie EJ, Stratton SL, Dignani MC, et al.: Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood 101(7): 2542-2546, 2003.
51. Wong-Beringer A, Kriengkauykiat J: Systemic antifungal therapy: new options, new challenges. Pharmacotherapy 23(11): 1441-1462, 2003.
52. Steinbach WJ, Stevens DA: Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 37(Suppl 3): S157-187, 2003.
53. Warnock DW: Amphotericin B: an introduction. J Antimicrob Chemother 28(Suppl B): 27-38, 1991.
54. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G: Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother 34(2): 183-188, 1990.
55. Eriksson U, Seifert B, Schaffner A: Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 322 (7286): 579-582, 2001.
56. Dick JD, Merz WG, Saral R: Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 18(1): 158-163, 1980.
57. Merz WG: Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol 20(6): 1194-1195, 1984.
58. Michailov G, Laporte JP, Lesage S, et al.: Autologous bone marrow transplantation is feasible in patients with a prior history of invasive pulmonary aspergillosis. Bone Marrow Transplant 17(4): 569-572, 1996.
59. Richard C, Romon I, Baro J, et al.: Invasive pulmonary aspergillosis prior to BMT in acute leukemia patients does not predict a poor outcome. Bone Marrow Transplant 12(3): 237-241, 1993.
60. Martino R, Nomdedeu J, Altes A, et al.: Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases. Bone Marrow Transplant 13(3): 265-269, 1994.
61. Cordonnier C, Beaune J, Offner F, Marinus A, Ljungman P, Meunier F: Aspergillosis prior to bone marrow transplantation. Infectious Diseases Working Party of the EBMT and the EORTC Invasive Fungal Infections Cooperative Group. Bone Marrow Transplant 16(2): 323-324, 1995.
62. Denning DW, Stevens DA: Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 12(6): 1147-1201, 1990.
63. Salerno CT, Ouyang DW, Pederson TS, et al.: Surgical therapy for pulmonary aspergillosis in immunocompromised patients. Ann Thorac Surg 65(5): 1415-1419, 1998.
64. Rousey SR, Russler S, Gottlieb M, Ash RC: Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 91(5): 484-492, 1991.
65. O'Donnell MR, Schmidt GM, Tegtmeier BR, et al.: Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 12(4): 827-834, 1994.
66. Riley DK, Pavia AT, Beatty PG, et al.: The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 97(6): 509-514, 1994.
67. Conneally E, Cafferkey MT, Daly PA, Keane CT, McCann SR: Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 5(6): 403-406, 1990.
68. Beyer J, Barzen G, Risse G, et al.: Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 37(6): 1367-1369, 1993.
69. Myers SE, Devine SM, Topper RL, et al.: A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma 8(3): 229-233, 1992.
70. Schwartz S, Behre G, Heinemann V, et al.: Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 93(11): 3654-3661, 1999.
71. Hiemenz JW, Walsh TJ: Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 22(Suppl 2): S133-144, 1996.
72. Tollemar J, Ringden O: Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Drug Saf 13(4): 207-218, 1995.
73. Wong-Beringer A, Jacobs RA, Guglielmo BJ: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 27(3): 603-618, 1998.
74. White MH, Anaissie EJ, Kusne S, et al.: Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 24 (4): 635-642, 1997.
75. Leenders AC, Daenen S, Jansen RL, et al.: Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103(1): 205-212, 1998.
76. Tiphine M, Letscher-Bru V, Herbrecht R: Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1(4): 273-283, 1999.
77. Manavathu EK, Cutright JL, Chandrasekar PH: Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother; 42(11): 3018-3021, 1998.
78. Como JA, Dismukes WE: Oral azole drugs as systemic antifungal therapy. N Engl J Med 330(4): 263-272, 1994.
79. Sheehan DJ, Hitchcock CA, Sibley CM: Current and emerging azole antifungal agents. Clin Microbiol Rev 12(1): 40-79, 1999.
80. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38 (2): 111-180, 2000.
81. Pfaller MA, Messer SA, Hollis RJ, et al.: Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis 33(4): 217-222, 1999.
82. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325(18): 1274-1277, 1991.
83. Persons DA, Laughlin M, Tanner D, Perfect J, Gockerman JP, Hathorn JW: Fluconazole and Candida krusei fungemia. N Engl J Med 325(18): 1315, 1991.
84. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R: Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 37(9): 1847-1849, 1993.
85. Denning DW, Hanson LH, Perlman AM, Stevens DA: In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 15(1): 21-34, 1992.
86. Rex JH, Bennett JE, Sugar AM, et al.: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331(20): 1325-1330, 1994.
87. Kontoyiannis DP, Bodey GP, Mantzoros CS: Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 44 (5): 125-135, 2001.
88. Zerr D, Garrison M, Marr KA, Christakis D; A meta-analysis of fluconazole versus amphotericin B for treatment of invasive Candida infection. J Clin Outcomes Manage 9: 191-196, 2002.
89. Goodman JL, Winston DJ, Greenfield RA, et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326(13): 845-851, 1992.
90. Slavin MA, Osborne B, Adams R, et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 171(6): 1545-1552, 1995.
91. Hansen JA, Gooley TA, Martin PJ, et al.: Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338 (14): 962-968, 1998.
92. Kanda Y, Yamamoto R, Chizuka A, et al.: Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 89(7): 1611-1625, 2000.
93. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S: Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 94(12): 3230-3246, 2002.
94. Van Cutsem J, Van Gerven F, Van de Ven MA, Borgers M, Janssen PA: Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother 26(4): 527-534, 1984.
95. Walsh TJ, Viviani MA, Arathoon E, et al.: New targets and delivery systems for antifungal therapy. Med Mycol 38(Suppl 1): 335-347, 2000.
96. Bailey EM, Krakovsky DJ, Rybak MJ: The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy 10(2): 146-153, 1990.
97. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K: Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 32(Suppl 1): 103-108, 1989.
98. Kanda Y, Kami M, Matsuyama T, et al.: Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol 16(1): 33-37, 1998.
99. Itraconazole. Med Lett Drugs Ther 35(888): 7-9, 1993.
100. Michallet M, Persat F, Kranzhofer N, et al.: Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. Bone Marrow Transplant 21 (12): 1239-1243, 1998.
101. Vandewoude K, Vogelaers D, Decruyenaere J, et al.: Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 41(12): 2714-2718, 1997.
102. Zhou H, Goldman M, Wu J, et al.: A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol 38(7): 593-602, 1998.
103. De Beule K, Van Gestel J: Pharmacology of itraconazole. Drugs 61(Suppl 1): 27-37, 2001.
104. Groll AH, Piscitelli SC, Walsh TJ: Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy 21(8 Pt 2): 133S-148S, 2001.
105. Tucker RM, Haq Y, Denning DW, Stevens DA: Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 26(4): 561-566, 1990.
106. Ahmad SR, Singer SJ, Leissa BG: Congestive heart failure associated with itraconazole. Lancet 357(9270): 1766-1767, 2001.
107. Nguyen MH, Yu CY: Voriconazole against fluconazole-susceptible and resistant Candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother 42(2): 253-256, 1998.
108. Denning DW, Venkateswarlu K, Oakley KL, et al.: Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 41(6): 1364-1368, 1997.
109. McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CR Jr, Rinaldi MG: In vitro activity of voriconazole against selected fungi. Med Mycol 36(4): 239-242, 1998.
110. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH: Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 37(12): 3946-3951, 1999.
111. Annaloro C, Oriana A, Tagliaferri E, et al.: Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica 80(6): 512-517, 1995.
112. Huijgens PC, Simoons-Smit AM, van Loenen AC, et al.: Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 52(5): 376-380, 1999.
113. Kaptan K, Ural AU, Cetin T, Avcu F, Beyan C, Yalcin A: Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia. J Infect Chemother 9(1): 40-45, 2003.
114. Nucci M, Biasoli I, Akiti T, et al.: A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 30(2): 300-305, 2000.
115. Vreugdenhil G, Van Dijke BJ, Donnelly JP, et al: Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 11(5-6): 353-358, 1993.
116. Glasmacher A, Prentice A, Gorschluter M, et al.: Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 21(24): 4615-4626, 2003.
117. Winston DJ, Maziarz RT, Chandrasekar PH, et al.: Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 138(9): 705-713, 2003.
118. Boogaerts M, Maertens J, van Hoof A, et al.: Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 48(1): 97-103, 2001.
119. Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al.: Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 44(7): 1887-1893, 2000.
120. Lass-Florl C, Gunsilius E, Gastl G, et al.: Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution. Ann Hematol 82(9): 565-569, 2003.
121. Marr KA, Crippa F, Leisenring W, et al.: Itraconazle versus fluconazole for prevention of fungal infection in allogeneic HSCT recipients: Results of randimized trial. Blood 100: 215a, 2002.
122. Menichetti F, Del Favero A, Martino P, et al.: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 28(2): 250-255, 1999.
123. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW: A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 105 (4): 901-911, 1999.
124. Poza G, Montoya J, Redondo C, et al.: Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin Infect Dis 30(6): 981-982, 2000.
125. Schwartz S, Milatovic D, Thiel E: Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 97(3): 663-665, 1997.
126. Goldstein JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52(4): 349-355, 2001.
127. Venkataramanan R, Zang S, Gayowski T, Singh N: Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 46 (9): 3091-3093, 2002.
128. Romero AJ, Pogamp PL, Nilsson LG, Wood N: Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 71(4): 226-234, 2002.
129. Espinel-Ingroff A: In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 36(1): 198-202, 1998.
130. Clancy CJ, Nguyen MH: In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 17(8): 573-575, 1998.
131. Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie EJ, Rex JH: Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility. J Clin Microbiol 37(9): 2755-2759, 1999.
132. Johnson EM, Szekely A, Warnock DW: In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 42(6): 741-745, 1998.
133. Walsh TJ, Pappas P, Winston DJ, et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346(4): 225-234, 2002.
134. Herbrecht R, Denning DW, Patterson TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (6): 408-415, 2002.
135. http://www.clinicaltrials.gov/ct/show/NCT00066599?order=16.
136. http://www.clinicaltrials.gov/ct/show/NCT00023530?order=4.
137. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH: A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 46(2): 229-234, 2000.
138. Marco F, Pfaller MA, Messer SA, Jones RN: In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi. Mycopathologia 141(2): 73-77, 1998.
139. Cacciapuoti A, Loebenberg D, Corcoran E, et al.: In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 44(8): 2017-2022, 2000.
140. Uchida K, Yokota N, Yamaguchi H: In vitro antifungal activity of posaconazole against various pathogenic fungi. Int J Antimicrob Agents 18(2): 167-172, 2001.
141. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ: In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 46(6): 1723-1727, 2002.
142. Espinel-Ingroff A, Fothergill A, Peter J, Rinaldi MG, Walsh TJ: Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol 40(9): 3204-3208, 2002.
143. Tortorano AM, Dannaoui E, Meletiadis J, et al.: Effect of medium composition on static and cidal activity of amphotericin B, itraconazole, voriconazole, posaconazole and terbinafine against Aspergillus fumigatus: a multicenter study. J Chemother 14(3): 246-252, 2002.
144. Espinel-Ingroff A, Rezusta A: E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J Clin Microbiol 40(6): 2101-2107, 2002.
145. Oakley KL, Moore CB, Denning DW: In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 41(5): 1124-1126, 1997.
146. Pfaller MA, Messer SA, Hollis RJ, Jones RN: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 46(4): 1032-1037, 2002.
147. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR: In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 46(5): 1581-1582, 2002.
148. Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie EJ, Loebenberg D, Rex JH: Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 43(3): 589-591, 1999.
149. Manavathu EK, Abraham OC, Chandrasekar PH: Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus. Clin Microbiol Infect 7(3): 130-137, 2001.
150. Ernst EJ: Investigational antifungal agents. Pharmacotherapy 21(8 Pt 2): 165S-174S, 2001.
151. Courtney R, Statkevich P, Laughlin M: Potential for a drug interaction between posaconazole and phenytoin (Abstract A-28). In: The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago: Washington DC: American Society for Microbiology; 2001.
152. Ezzet F, Wexler D, Courtney R: The pharmacokinatics of posaconazole in neutropenic oncology patients (Abstract A-26). In: The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago: Washington DC: American Society for Microbiology; 2001.
153. Courtney R, Pai S, Laughlin M, Lim J, Batra V: Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 47 (9): 2788-2795, 2003.
154. Hachem R, Raad I, Afif C: An open, non-comparative multicenter study to evaluate efficacy and safety of possaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intelerant to standard therapy (Abstract 1109). In: The 40th Interscicence Conference on Antimicrobial Agents and Chemotherapy; 2000; Tronto: Washington DC: American Society for Microbiology; 2000.
155. http://www.clinicaltrials.gov/ct/show/NCT00034632?order=32.
156. Hudyma T: BMS-292655, a soluble prodrug of the clinically efficacious antifungal triazole, BMS-207147 (Ravuconazole). In: The 42th Interscience Conference on Antimicrobial Agents and Chemotherapy (Abstract-2247); 2002; San Diego: Washington DC: American Society for Microbiology; 2002.
157. Ueda Y: BMS-379224, a water-soluble prodrug of ravuconazole (Abstract-1214). In: The 42th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego: Washington DC: American Society for Microbiology; 2002.
158. Moore CB, Walls CM, Denning DW: In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 44(2): 441-443, 2000.
159. Arikan S, Rex JH: Ravuconazole Eisai/Bristol-Myers Squibb. Curr Opin Investig Drugs 3(4): 555-561, 2002.
160. Hata K, Ueno H, Miki T, et al.: ER-30346, a novel antifungal triazole: III. In vitro activity and its mode of action. In: The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995: Washington DC:
161. Olsen S, Mummaneni V, Rolan P, Norton J, Grasela D: Ravuconazole single ascending oral dose study in healthy subjects. In: The 40th Interscience Conference on Antimicrobial Agents and Chemotherapy.; 2000; Tronto, Canada: Washington DC: American Society for Microbiology; 838, 2000.
162. Grasela D, Olsen S, Mummaneni V: Ravuconazole: multiple ascending oral dose study in healthy subjects (abstr). In: Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy.; 2000 September 17-20, 2000.; Tronto: Washington DC: American Society for Microbiology; 839, 2000.
163. Mummaneni V, Geraldes M, Hadijilambris O, Ouyang Z, Uderman H, Marino M: Effect of ravuconazole on the pharmacokinetics of simvastatin in healthy subjects (Abstract 841). In: The 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Tronto: Washington DC: American Society for Microbiology; 2000.
164. Fung-Tomc JC, Huczko E, Minassian B, Bonner DP: In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother 42(2): 313 -318, 1998.
165. Pfaller MA, Messer SA, Hollis RJ, et al.: In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 42(12): 3242-3244, 1998.
166. Hata K, Kimura J, Miki H, Toyosawa T, Nakamura T, Katsu K: In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother 40 (10): 2237-2242, 1996.
167. http://www.clinicaltrials.gov/ct/show/NCT00061555?order=15.
168. http://clinicalstudies.info.nih.gov/detail/A_2003-C-0205.html.
169. Groll AH, Mickiene D, Petraitis V, et al.: Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK 463) in rabbits. Antimicrob Agents Chemother 45 (12): 3322-3327, 2001.
170. Groll AH, Gullick BM, Petraitiene R, et al.: Compartimental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother 45(2): 596-600, 2001.
171. Tawara S, Ikeda F, Maki K, et al.: In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 44(1): 57-62, 2000.
172. Mikamo H, Sato Y, Tamaya T: In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 46(3): 485-487, 2000.
173. Uchida K, Nishiyama Y, Yokota N, Yamaguchi H: In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot (Tokyo) 53(10): 1175-1181, 2000.
174. Maki K, Morishita Y, Iguchi Y, et al.: In vitro antifungal activity of FK463, a novel water-soluble echinocandin-like lipopeptide (Abstract 268). In: The 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998; San Diego: Washington DC: American Society for Microbiology; 1998.
175. Nishiyama Y, Uchida K, Yamaguchi H: Morphological changes of Candida albicans induced by micafungin (FK-463), a water-soluble echinocandin-like lipopeptide. J Electron Microsc (Tokyo) 51(4): 247-255, 2002.
176. Watabe E, Nakai T, Matsumoto S, Ikeda F, Hatano K: Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother 47(6): 1995-1998, 2003.
177. Tomishima M, Ohki H, Yamada A, et al.: FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J Antibiot (Tokyo) 52(7): 674 -676, 1999.
178. Nakai T, Uno J, Otomo K, et al.: In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 48(2): 78-81, 2002.
179. Ikeda F, Wakai Y, Matsumoto S, et al.: Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 44(3): 614-618, 2000.
180. Petraitis V, Petraitiene R, Groll AH, et at.: Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 46(6): 1857-1869, 2002.
181. Matsumoto S, Wakai Y, Nakai T, et al.: Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 44(3): 619-621, 2000.
182. Powles R, Sirohi B, Chopra R, Russel N, Prentice H: Assessment of maximum tolerated dose of FK463 in cancer patients undergoing haematopoietic stem cell transplantation (Abstract 676). In: The 41th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago: Washington DC: American Society for Microbiology; 2001.
183. Kohno S, Masaoka T, Yamaguchi H: A multicenter open-label clinical study of FK463 in patients with deep mycoses in Japan (Abstract J-834). In: The 41th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago: Washington DC: American Society for Microbiology; 2001.
184. van Burik JA, Ratanatharathorn V, Lipton J, Miller CB, Bunn N, Walsh TJ: Randomized, double-blind trial of micafungin (MI) versus fluconazole (FL) for prophylaxis of invasive fungal infections in patients (pts) undergoing hematopoietic stem cell transplantation (HSCT), NIAID/BAMSG Protocol 46. In: The 42st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego: Washington DC: American Society for Microbiology; 2002.
185. Sanglard D, Odds FC: Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2(2): 73-85, 2002.
186. Daly A, McAfee S, Dey B, et al.: Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 9(6): 373-382, 2003.
187. Junghanss C, Marr KA, Carter RA, et al.: Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 8(9): 512-520, 2002.
188. Mielcarek M, Martin PJ, Leisenring W, et al.: Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102(2): 756-762, 2003.
189. Nakai K, Mineishi S, Kami M, et al.: Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Transplantation 75(12): 2135-2144, 2003.
190. Kami M, Sawada Y, Mori S, et al.: Serum levels of fluconazole in patients after cytotoxic chemotherapy for hematological malignancy. Am J Hematol 66(2): 85-91, 2001.
191. Marr KA, Seidel K, Slavin MA, et al.: Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96 (6): 2055-2061, 2000.